Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.
Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.
Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.
Canada-based Cynapsus has come up with the first sublingual option for the delivery of apomorphine to patients with Parkinson's disease to control their debilitating "off" episodes. This week, the company heralded results from a study comparing the thin film strip with a subcutaneous injection of the same drug, noting a reduction in side effects.
Civitas Therapeutics picked up $38 million in second-round financing to finish a Phase IIb trial and begin Phase III for its ARCUS respiratory delivery platform to treat Parkinson's disease.
Civitas Therapeutics heralded a successful Phase II trial result for its inhaled Parkinson's drug CVT-301, the novel delivery of which promises to make the disease more manageable for patients on an everyday basis, the company says.
Civitas Therapeutics generated positive top line results in a Phase I trial of CVT-301, its inhaled version of L-dopa to treat Parkinson's disease-related tremors. The drug, which is ingested through
Civitas Therapeutics has secured new funding from The Michael J. Fox Foundation for Parkinson's Research, which will support clinical testing of its inhaled Parkinson's therapy through the...